1. 9PPlasma gene conversions after one cycle (C) abiraterone acetate (AA) for metastatic castration-resistant prostate cancer (mCRPC): A biomarker analysis of a multi-centre, international trial. (7th November 2019) Authors: Jayaram, A K; Shen, D; Wingate, A; Wetterskog, D; Sternberg, C; Jones, R; Berruti, A; Lefresne, F; Lahaye, M; Thomas, S; Joshi, S; Gormley, M; Tombal, B; Merseburger, A; Ricci, D; Attard, G Journal: Annals of oncology Issue: Volume 30(2019)Supplement 7 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. (23rd October 2017) Authors: Armstrong, A J; Antonarakis, E S; Taplin, M -E; Kelly, W K; Beltran, H; Fizazi, K; Dahut, W L; Shore, N; Slovin, S; George, D; Carducci, M A; Corn, P; Danila, D; Dreicer, R; Heath, E; Rathkopf, D; Liu, G; Nanus, D; Stein, M; Smith, M R Journal: Annals of oncology Issue: Volume 29:Number 1(2018) Page Start: 23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗